



02-23-04

-214w  
\$

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DENNIS  
Serial No.: 10/639,076  
Filed: AUGUST 11, 2003  
Confirmation No.: 6938  
Title: FVIIA ANTAGONISTS

Examiner: H. ROBINSON  
Group Art Unit: 1656  
Docket: 11669.232USC1  
Customer No.: 23552

## CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 639593694 US

Date of Deposit: February 21, 2006

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

By:

Name: Sheryl A. Boerboom

Mail Stop Amendments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**23552**

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement, Form 1449, 59 References
- ☒ Check in the amount of \$180.00 for payment of information disclosure statement fee
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.


Merchant & Gould P.C.  
P.O. Box 2903  
Minneapolis, MN 55402-0903  
612.332.5300

By:

Name: Katherine M. Kowalchyk

Reg. No.: 36,848

KKowalchyk:sab



S/N 10/639,076

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant:	DENNIS	Examiner:	H. ROBINSON
Serial No.:	10/639,076	Group Art Unit:	1656
Filed:	AUGUST 11, 2003	Docket No.:	11669.232USC1
Confirmation No.:	6938	Customer No.:	23552
Title:	FVIIA ANTAGONISTS		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 639593694 US

Date of Deposit: February 21, 2006

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

By:   
Name: Sheryl A. Boerboom

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop Amendments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

02/27/2006 EXAMED1 00000094 10539076

01 FC:1806

180.00 CP

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: February 21, 2006

Katherine M. Kowalchyk  
Katherine M. Kowalchyk  
Reg. No. 36,848



FORM 1449\*

## INFORMATION DISCLOSURE STATEMENT

## IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.232USC1

Application Number:

10/639,076

Applicant: DENNIS

Filing Date: 08/11/2003

Group Art Unit: 1656

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,972,859	08/03/1976	Fujino et al.			
	4,105,603	08/08/1978	Vale, Jr. et al.			
	4,399,216	08/16/1983	Axel et al.			
	5,122,614	06/16/1992	Zalipsky			
	5,288,931	02/22/1994	Chang et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 278 776	08/17/1988	EP				
	0 307 247	03/15/1989	EP				
	WO 89/05859	06/29/1989	PCT				
	WO 90/01940	03/08/1990	PCT				
	WO 01/01749 A2/A3	01/11/2001	PCT				
	WO 01/10892 A2/A3	02/15/2001	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Abrahmsen, "Analysis of signals for secretion in the staphylococcal protein A" <u>The EMBO Journal</u> 4:3901-3906 (1985)
	Appleyard, R.K., "Segregation of new lysogenic types during growth of a doubly lysogenic strain derived from escherichia coli K12" <u>Genetics</u> 39:440-452 (1954)
	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1996)
	Carter, "American Chemical Society Symposium Series No. 427" <u>Protein Purification: from Molecular Mechanisms to Large-Scale Processes</u> , Ladisch et al., Eds., Chapter 13, pps. 181-193 (1990)
	Castellanos-Serra et al., "Expression and folding of an interleukin-2-proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the C-peptide and the N-terminal fused sequence" <u>FEBS Letters</u> 378:171-176 (1996)
	Davie, E.W., "Biochemical and molecular aspects of the coagulation cascade" <u>Thrombosis and Haemostasis</u> 74:1-6 (1995)
	Dennis et al., "Selection of characterization of new class of peptide exosite inhibitors of coagulation factor VIIa" <u>Biochemistry</u> 40:9513-9521 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 11669.232USC1	Application Number: 10/639,076
	Applicant: DENNIS	
	Filing Date: 08/11/2003	Group Art Unit: 1656

	Edgington, T.S. et al., "The structural basis of function of the TFVIIa complex in the cellular initiation of coagulation" <u>Thrombosis and Hemostasis</u> 78:401-405 (1997)
	Eigenbrot, C. et al., "The factor VII zymogen structure reveals reregistration of B strands during activation" <u>Structure</u> 9:627-636 (2001)
	Engels et al., "Gene synthesis" <u>Agnew, Chem. Int. Ed. Engl.</u> 28:716-734 (1989)
	Ganong, "Regulation of gastrointestinal function" <u>Review of Medical Physiology</u> , Lange, 13 edition, Los Altos, California, Chapter 26, pps. 411-414 (1987)
	Graham et al., "Characteristics of human cell line transformed by DNA from human adenovirus type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977)
	Greene, "Protection from the amino group" <u>Protective groups in organic synthesis</u> , 2nd edition, New York: John Wiley & sons pps. 309-405 (1991)
	Harris, J.L., "Definition and redesign of the extended substrate specificity of grazyme B" <u>Journal of Biological Chemistry</u> 273:27364-27373 (1998)
	Houghten, "General Method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids" <u>Proc. Natl. Acad. Sci. USA</u> 82:5131-5135 (Aug. 1985)
	Hsiao et al., "High-frequency transformation of yeast by plasmids containing the cloned yeast ARF4 gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979)
	Husbyn et al., "Peptides corresponding to the second epidermal growth factor-like domain of human blood coagulation factor VII: synthesis, folding and biological activity" <u>J. Peptide Res.</u> 50:475-482 (1997)
	Ke, S.H., "Optimal subsite occupancy and design of a selective inhibitor of Urokinase" <u>Journal of Biological Chemistry</u> 272:20456-20462 (1997)
	Kelley, R.F., "Folding of eukaryotic proteins produced in Escherichia coli" <u>Genetic Engineering Principles and Methods</u> , Setlow, J.M., New York: Plenum Press Vol. 12:1-19 (1990)
	Kridel, S.J., "A substrate phage enzyme-linked immunosorbent assay to profile panels of proteases" <u>Analytical Biochemistry</u> 294:176-184 (2001)
	Kunkel et al., "Efficient site-directed mutagenesis using uracil-containing DNA" <u>Methods in Enzymology</u> 204:125-139 (1991)
	Kunkel et al., "Rapid and efficient site-specific mutagenesis without phenotypic selection" <u>Methods in Enzymology</u> 154:367-382 (1987)
	Lehninger, A.L., "The amino acid building blocks of protein" <u>Biochemistry</u> , 2nd edition, New York, New York: Worth Publishers pps. 71-92 (1975)
	Lowman and Wells, "Affinity maturation of human growth hormone by monovalent phage display" <u>J. Mol. Biol.</u> 234:564-578 (1993)
	Mann, K.G., "Biochemistry and Physiology of Blood Coagulation" <u>Thrombosis and Hemostasis</u> 82:165-174 (1999)
	Mather et al., "Culture of testicular cells in hormone-supplemented serum-free medium" <u>Annals N.Y. Acad. Sci.</u> 383:44-68 (1982)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 11669.232USC1	Application Number: 10/639,076
	Applicant: DENNIS	
	Filing Date: 08/11/2003	Group Art Unit: 1656

	Mather, J.P., "Establishment and characterization of two distinct mouse testicular epithelial cell lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
	Matthews et al., "Substrate phage: selection of protease substrates by monovalent phage display" <u>Science</u> 260:1113-1117 (1993)
	Merrifield, R.B., "Solid phase peptide synthesis: the synthesis of a tetrapeptide" <u>J. Am. Chem. Soc.</u> 85:2149-2154 (1964)
	Messing et al., "A system for shotgun DNA sequencing" <u>Nucleic Acid Research</u> 9:309-321 (1981)
	Neuenschwander et al., "Importance of substrate composition, pH and other variables on tissue factor enhancement of factor VIIa activity" <u>Thrombosis and Haemostasis</u> 71:970-977 (1993)
	Nilsson and Abrahmsen, "Fusions to staphylococcal protein A" <u>Meth. Enzymol.</u> 185:144-161 (1990)
	Nilsson et al., "A synthetic YgG-binding domain based on staphylococcal protein A" <u>Protein Eng.</u> 1:107-113 (1987)
	Nilsson et al., "Integrated production of human insulin and its C-peptide" <u>Journal of Biotechnology</u> 48:241-250 (1996)
	Pelton et al., "Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for $\mu$ opoid receptors" <u>J. Med. Chem.</u> 29:2370-2375 (1986)
	Presta et al., "Generation of humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic" <u>Thrombosis and Haemostasis</u> 85(3):379-389 (Mar. 2001)
	Rapaport and Rao "The tissue factor pathway: how it has become a "prima ballerina"" <u>Thrombosis and Haemostasis</u> 74:7-17 (1995)
	Roberge, M. et al., "A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors" <u>Biochemistry</u> 40:9522-9531 (2001)
	Roberts and Vellaccio, "Unusual amino acids in peptide synthesis" <u>The Peptides: Analysis, Synthesis, Biology, Gross and Meiehofer</u> , Academic Press Inc., New York, New York, Chapter 6, Vol. 5:341-449 (1983)
	Sambrook et al., <u>Molecular Cloning: A Laboratory Manual</u> , 2nd edition, New York: Cold Spring Harbor Laboratory Press pps. 1.36-1.52 (1989)
	Shaw et al., "A general method for the transfer of cloned genes to plant cells" <u>Gene</u> 23:315-330 (1983)
	Smith B.J., "Enzymatic methods for cleaving proteins" <u>Methods Mol. Biol.</u> 32:289-296 (1994)
	Smith, M.M., "Rapid identification of highly active selective substrates for stromelysin and matrilysin using bacteriophage peptide display libraries" <u>J. Bio. Chem.</u> 270:6440-6449 (1995)
	Starovasnik et al., "Antibody variable region binding by staphylococcal protein A: thermodynamic analysis and location of the Fv binding site on E-domain" <u>Protein Sci.</u> 8:1423-1431 (1999)
	Stewart, J.M. and Young, J.D., <u>Solid Phase Peptide Synthesis</u> , 2nd edition, Pierce Chemical Co., pps. 1-176 (1984)
	Suva, L.J. et al., "A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression" <u>Science</u> 237:893-896 (1987)
	Urlaub et al., "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity" <u>Proc. Natl. Acad. Sci. USA</u> 77:4216-4220 (1980)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 11669.232USC1	Application Number: 10/639,076
	Applicant: DENNIS	
	Filing Date: 08/11/2003	Group Art Unit: 1656

	Van Solingen, "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)
	Varadarajan et al., "Cloning, expression in Escherichia coli, and reconstitution of human myoglobin" <u>Proc. Natl. Acad. Sci. USA</u> 82:5681-5684 (1985)
	Wearley L.L., "Recent progress in protein and peptide delivery by noninvasive routes" <u>Crit. Rev. in Ther. Drug Carrier Systems</u> 8:331-394 (1991)
	Wells, J. et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. Royal Soc. London Ser. A</u> 317:415-423 (1986)
	Wells J.A. et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites" <u>Gene</u> 34:315-323 (1985)
	Zoller, "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutation in any fragment of DNA" <u>Nucl. Acids Research</u> 10:6487-6500 (1982)



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	